Monocentric Retrospective Observational Study Describing the Visual Acuity of Patients With Exudative Age Related Macular Degeneration and Treated by Lucentis® Under Real Conditions of Care.

Hospital St. Joseph, Marseille, France1 site in 1 country250 target enrollmentMarch 2014

ConditionsExudative Age-Related Macular Degeneration

Overview

Phase: N/A
Intervention: Not specified
Conditions: Exudative Age-Related Macular Degeneration
Sponsor: Hospital St. Joseph, Marseille, France
Enrollment: 250
Locations: 1
Primary Endpoint: Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative Age-Related Macular Degeneration (ARMD), treated with Lucentis, under real conditions of care, in terms of mean change of the Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).

Registry

clinicaltrials.gov

Start Date

March 2014

End Date

December 2014

Last Updated

12 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hospital St. Joseph, Marseille, France

Responsible Party

Principal Investigator

QUEGUINER, MD

Ophtalmologist

Hospital St. Joseph, Marseille, France

Eligibility Criteria

Inclusion Criteria

•Patients with exudative-subfove ARMD, regardless the neovessel type or the initial visual acuity; 2 - Patients treated in the department with intra vitreous injection of Lucentis ® during the study period (08/2011 and 02/2013); 3 - If both eyes are eligible, both will be analyzed;

Exclusion Criteria

•Patients who received, for the studied eye, a treatment with a Vascular endothelial growth factor (VEGF) other than Lucentis ® in the three months preceding the start of the study. For those who received combination therapy, the nature of the treatment will be specified and taken into account in the subgroups for statistical analyzes;
•Patients with high myopia or neovessel not related to exudative-ARMD;